Literature DB >> 29685876

Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.

Bryant R England1,2, Geoffrey M Thiele1,2, Daniel R Anderson3, Ted R Mikuls4,2.   

Abstract

Rheumatoid arthritis is a systemic autoimmune disease characterized by excess morbidity and mortality from cardiovascular disease. Mechanisms linking rheumatoid arthritis and cardiovascular disease include shared inflammatory mediators, post-translational modifications of peptides/proteins and subsequent immune responses, alterations in the composition and function of lipoproteins, increased oxidative stress, and endothelial dysfunction. Despite a growing understanding of these mechanisms and their complex interplay with conventional cardiovascular risk factors, optimal approaches of risk stratification, prevention, and treatment in the context of rheumatoid arthritis remain unknown. A multifaceted approach to reduce the burden posed by cardiovascular disease requires optimal management of traditional risk factors in addition to those intrinsic to rheumatoid arthritis such as increased disease activity. Treatments for rheumatoid arthritis seem to exert differential effects on cardiovascular risk as well as the mechanisms linking these conditions. More research is needed to establish whether preferential rheumatoid arthritis therapies exist in terms of prevention of cardiovascular disease. Ultimately, understanding the unique mechanisms for cardiovascular disease in rheumatoid arthritis will aid in risk stratification and the identification of novel targets for meaningful reduction of cardiovascular risk in this patient population. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Year:  2018        PMID: 29685876      PMCID: PMC6889899          DOI: 10.1136/bmj.k1036

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  178 in total

1.  Association of Light-Intensity Physical Activity With Lower Cardiovascular Disease Risk Burden in Rheumatoid Arthritis.

Authors:  Samannaaz S Khoja; Gustavo J Almeida; Mary Chester Wasko; Lauren Terhorst; Sara R Piva
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-04       Impact factor: 4.794

2.  Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages.

Authors:  Iryna Voloshyna; Sony Modayil; Michael J Littlefield; Elise Belilos; Kristina Belostocki; Lois Bonetti; Gary Rosenblum; Steven E Carsons; Allison B Reiss
Journal:  Exp Biol Med (Maywood)       Date:  2013-09-02

3.  Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial.

Authors:  Naomi B Klarenbeek; Sjoerd M van der Kooij; Tineke J W Huizinga; Yvonne P M Goekoop-Ruiterman; Harry M J Hulsmans; Michiel V van Krugten; Irene Speyer; Jeska K de Vries-Bouwstra; Pit J S M Kerstens; Tom W J Huizinga; Ben A C Dijkmans; Cornelia F Allaart
Journal:  Ann Rheum Dis       Date:  2010-05-14       Impact factor: 19.103

4.  Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies.

Authors:  Juan Antonio Avina-Zubieta; Jamie Thomas; Mohsen Sadatsafavi; Allen J Lehman; Diane Lacaille
Journal:  Ann Rheum Dis       Date:  2012-03-16       Impact factor: 19.103

5.  Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis.

Authors:  Lisa A Davis; Grant W Cannon; Lauren F Pointer; Leah M Haverhals; Roger K Wolff; Ted R Mikuls; Andreas M Reimold; Gail S Kerr; J Steuart Richards; Dannette S Johnson; Robert Valuck; Allan Prochazka; Liron Caplan
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

6.  Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.

Authors:  Christina Charles-Schoeman; Xiaoyan Wang; Yuen Yin Lee; Ani Shahbazian; Iris Navarro-Millán; Shuo Yang; Lang Chen; Stacey S Cofield; Larry W Moreland; James O'Dell; Joan M Bathon; Harold Paulus; S Louis Bridges; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

7.  Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients.

Authors:  Tarun S Sharma; Mary Chester M Wasko; Xiaoqin Tang; Deepak Vedamurthy; Xiaowei Yan; Jonida Cote; Androniki Bili
Journal:  J Am Heart Assoc       Date:  2016-01-04       Impact factor: 5.501

8.  Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.

Authors:  Audrey S L Low; Deborah P M Symmons; Mark Lunt; Louise K Mercer; Chris P Gale; Kath D Watson; William G Dixon; Kimme L Hyrich
Journal:  Ann Rheum Dis       Date:  2017-01-10       Impact factor: 19.103

9.  Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis.

Authors:  Yoon Kang; Hee-Jin Park; Mi-I Kang; Hyang-Sun Lee; Sang-Won Lee; Soo-Kon Lee; Yong-Beom Park
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

10.  Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.

Authors:  Iain B McInnes; Liz Thompson; Jon T Giles; Joan M Bathon; Jane E Salmon; Andre D Beaulieu; Christine E Codding; Timothy H Carlson; Christian Delles; Janet S Lee; Naveed Sattar
Journal:  Ann Rheum Dis       Date:  2013-12-24       Impact factor: 19.103

View more
  86 in total

Review 1.  Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease.

Authors:  Holly Anderton; Ian P Wicks; John Silke
Journal:  Nat Rev Rheumatol       Date:  2020-07-08       Impact factor: 20.543

2.  Vascular Arginase Is a Relevant Target to Improve Cerebrovascular Endothelial Dysfunction in Rheumatoid Arthritis: Evidence from the Model of Adjuvant-Induced Arthritis.

Authors:  Romain Bordy; Aurore Quirié; Christine Marie; Daniel Wendling; Perle Totoson; Céline Demougeot
Journal:  Transl Stroke Res       Date:  2019-03-18       Impact factor: 6.829

3.  Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019.

Authors:  Dalton Bertolim Précoma; Gláucia Maria Moraes de Oliveira; Antonio Felipe Simão; Oscar Pereira Dutra; Otávio Rizzi Coelho; Maria Cristina de Oliveira Izar; Rui Manuel Dos Santos Póvoa; Isabela de Carlos Back Giuliano; Aristóteles Comte de Alencar Filho; Carlos Alberto Machado; Carlos Scherr; Francisco Antonio Helfenstein Fonseca; Raul Dias Dos Santos Filho; Tales de Carvalho; Álvaro Avezum; Roberto Esporcatte; Bruno Ramos Nascimento; David de Pádua Brasil; Gabriel Porto Soares; Paolo Blanco Villela; Roberto Muniz Ferreira; Wolney de Andrade Martins; Andrei C Sposito; Bruno Halpern; José Francisco Kerr Saraiva; Luiz Sergio Fernandes Carvalho; Marcos Antônio Tambascia; Otávio Rizzi Coelho-Filho; Adriana Bertolami; Harry Correa Filho; Hermes Toros Xavier; José Rocha Faria-Neto; Marcelo Chiara Bertolami; Viviane Zorzanelli Rocha Giraldez; Andrea Araújo Brandão; Audes Diógenes de Magalhães Feitosa; Celso Amodeo; Dilma do Socorro Moraes de Souza; Eduardo Costa Duarte Barbosa; Marcus Vinícius Bolívar Malachias; Weimar Kunz Sebba Barroso de Souza; Fernando Augusto Alves da Costa; Ivan Romero Rivera; Lucia Campos Pellanda; Maria Alayde Mendonça da Silva; Aloyzio Cechella Achutti; André Ribeiro Langowiski; Carla Janice Baister Lantieri; Jaqueline Ribeiro Scholz; Silvia Maria Cury Ismael; José Carlos Aidar Ayoub; Luiz César Nazário Scala; Mario Fritsch Neves; Paulo Cesar Brandão Veiga Jardim; Sandra Cristina Pereira Costa Fuchs; Thiago de Souza Veiga Jardim; Emilio Hideyuki Moriguchi; Jamil Cherem Schneider; Marcelo Heitor Vieira Assad; Sergio Emanuel Kaiser; Ana Maria Lottenberg; Carlos Daniel Magnoni; Marcio Hiroshi Miname; Roberta Soares Lara; Artur Haddad Herdy; Cláudio Gil Soares de Araújo; Mauricio Milani; Miguel Morita Fernandes da Silva; Ricardo Stein; Fernando Antonio Lucchese; Fernando Nobre; Hermilo Borba Griz; Lucélia Batista Neves Cunha Magalhães; Mario Henrique Elesbão de Borba; Mauro Ricardo Nunes Pontes; Ricardo Mourilhe-Rocha
Journal:  Arq Bras Cardiol       Date:  2019-11-04       Impact factor: 2.000

4.  Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial.

Authors:  Dženan Mašić; Kristian Stengaard-Pedersen; Brian Bridal Løgstrup; Kim Hørslev-Petersen; Merete Lund Hetland; Peter Junker; Mikkel Østergaard; Christian Ammitzbøll; Sören Möller; Robin Christensen; Torkell Ellingsen
Journal:  Rheumatol Int       Date:  2021-01-02       Impact factor: 2.631

Review 5.  Cardiovascular effects of approved drugs for rheumatoid arthritis.

Authors:  Fabiola Atzeni; Javier Rodríguez-Carrio; Călin D Popa; Michael T Nurmohamed; Gabriella Szűcs; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2021-04-08       Impact factor: 20.543

Review 6.  Effect of vitamin E supplementation in rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Rui Zhang; Jianbing Ma; Haiyang Kou; Zhong Qing; Hao Guo
Journal:  Eur J Clin Nutr       Date:  2022-04-25       Impact factor: 4.016

7.  Immune Modulation of Coronary Atherosclerosis With Anticytokine Treatment.

Authors:  Mohamed A Zayed
Journal:  Circ Cardiovasc Imaging       Date:  2020-09-15       Impact factor: 7.792

8.  LncRNA MIAT downregulates IL-1β, TNF-ɑ to suppress macrophage inflammation but is suppressed by ATP-induced NLRP3 inflammasome activation.

Authors:  Ziye Wang; Yang Kun; Zhao Lei; Wen Dawei; Pan Lin; Wang Jibo
Journal:  Cell Cycle       Date:  2021-01-18       Impact factor: 4.534

9.  Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study.

Authors:  Dorien M C F Sluijsmans; Daphne C Rohrich; Calin D Popa; Bart J F van den Bemt
Journal:  J Clin Med       Date:  2021-05-05       Impact factor: 4.241

10.  Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival.

Authors:  Bryant R England; Harlan Sayles; Kaleb Michaud; Geoffrey M Thiele; Jill A Poole; Liron Caplan; Brian C Sauer; Grant W Cannon; Andreas Reimold; Gail S Kerr; Joshua F Baker; Ted R Mikuls
Journal:  Clin Rheumatol       Date:  2018-10-02       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.